Analgesic and Anti-inflammatory Efficacy of a Combined Herbal Formulation Containing Moringa oleifera and Celastrus paniculatus Seed Oils

N
Neetu Pandey1,*
S
Santosh K. Karn2
R
Ritika Mehra1
P
Pradyumna Ghosal1
1Department of Applied Chemistry and Basic Sciences, School of Basic and Life Sciences, Sardar Bhagwan Singh University, Dehradun-248 019, Uttrakhand, India.
2Department of Biochemistry and Biotechnology, School of Basic and Life Sciences, Sardar Bhagwan Singh University, Dehradun-248 019, Uttrakhand, India.

Background: Herbal seed oils have attracted interest as potential sources of bioactive compounds with analgesic and anti-inflammatory properties. Moringa oleifera and Celastrus paniculatus have individually been investigated for pharmacological activities; however, the activity of a topical formulation containing their seed oils warrants further experimental evaluation. The present study evaluated the preliminary analgesic and anti-inflammatory activity and short-term topical tolerability of formulations containing combined Moringa oleifera and Celastrus paniculatus seed oils.

Methods: Topical formulations containing 1%, 2% and 3% combined seed oils were evaluated in experimental animal models of nociception and inflammation. Diclofenac was included as a reference treatment. Analgesic activity was assessed using the hot-plate test, while anti-inflammatory activity was evaluated using carrageenan-induced paw edema. Basic physicochemical characteristics and short-term topical tolerability were also assessed.

Result: The combined seed-oil formulations demonstrated measurable analgesic and anti-inflammatory activity compared with the control treatment, with the magnitude of response varying according to formulation concentration and observation time. Among the concentrations tested, the 2% formulation showed the strongest overall response in the experimental models. However, responses were not consistently greater at 3%, indicating that increasing formulation concentration did not necessarily result in a proportional increase in activity. The formulation did not produce observable acute local irritation under the conditions evaluated.

Pain is one of the most common symptoms encountered in clinical practice and has traditionally been managed using medicinal plants and herbal preparations. Although conventional analgesic and non-steroidal anti-inflammatory drugs (NSAID), are widely used, their prolonged use may be associated with adverse effects, creating continued interest in safer and potentially effective plant-based alternatives (Abdul et al., 2021). Among medicinal plants, Moringa oleifera and Celastrus paniculatus have attracted attention because of their reported analgesic and anti-inflammatory properties (Abebe, 2002).
       
Moringa oleifera
(Moringaceae) is a medicinal plant rich in biologically active constituents, including alkaloids, glycosides, phenolic compounds, saponins and tannins (Kanitta and Wannee, 2016, Ugwuoke et al., 2020, Rathaur, 2024). Previous studies have reported its analgesic and anti-inflammatory potential, suggesting that its phytochemical constituents may contribute to modulation of pain and inflammation (Dwivedi and Maurya, 2018). Similarly, Celastrus paniculatus is a medicinal shrub whose seeds and seed oil have traditionally been used in Ayurveda for various disorders, including applications related to neurological and pain-associated conditions (Kulkarni et al., 2015). Phytochemical investigations have identified alkaloids and other bioactive constituents in Celastrus paniculatus, while experimental studies have reported analgesic and anti-inflammatory effects of its extracts (Ahmad et al., 1994; Nagpal et al., 2022).
       
The pharmacological activities reported for these two botanically distinct plants provide a scientific basis for investigating their use together in a topical formulation. However, the rationale for their combination should be distinguished from a claim of pharmacological synergy. Although both plants have individually demonstrated analgesic and/or anti-inflammatory potential, the present study was not designed to establish whether their interaction is synergistic, additive, antagonistic, or simply reflects the combined effects of their constituents. Demonstration of synergy would require appropriate individual-oil comparator groups and a predefined method for assessing drug interaction.
       
Topical delivery of plant-derived oils may provide a convenient approach for local application while avoiding some limitations associated with systemic administration. Despite reports on the individual biological activities of Moringa oleifera and Celastrus paniculatus, limited experimental information is available on their combined seed oils incorporated into a topical cream and evaluated for analgesic and anti-inflammatory activity in vivo. Therefore, the present study focuses on the development and preliminary evaluation of such a combined formulation rather than claiming a synergistic effect.
       
Accordingly, the objective of the present study was to formulate topical creams containing combined Moringa oleifera and Celastrus paniculatus seed oils at different concentrations and to evaluate their preliminary analgesic and anti-inflammatory activities using the hot-plate test and carrageenan-induced paw-Edema models in Wistar albino rats.
Drugs and chemicals
 
All chemicals and reagents used in the present study were of analytical grade. Methyl paraben, liquid paraffin, polyethene glycol (PEG), beeswax, borax, petroleum ether, citric acid and distilled water were utilised in the experimental work. All the chemicals were procured from the laboratory of Sardar Bhagwan Singh University, Balawala, Dehradun, India and were used without further purification. All reagents were stored under appropriate conditions as per standard laboratory protocols to ensure stability and reliability of results. All experimental work was carried out in the laboratory of Sardar Bhagwan Singh University, Balawala, Dehradun, India in the year between 2025-2026.
 
Collection and identification
 
The plant seeds of Moringa oleifera were obtained from the campus of Sardar Bhagwan Singh University (SBSU), Dehradun, India and Celastrus paniculatus were obtained from the Swami Ram Teerth, (SRT) campus Botanical Garden, Badshahtithaul Tehri Garwal, Uttarakhand, India. The authentication of the given seeds plants was done through Botanical Survey India, (BSI) Dehradun, Uttarakhand, India and ICFRE-Forest Research Institute  Dehradun, Uttarakhand, India. Authentication number for Moringa oleifera was BSI/NRC.Herb(Ident.)/2024-25/646 and Authentication number for Celastrus paniculatus was 790/Dis./2026-27/Syst.Bot./Rev.Gen./4-5.
 
Animals
 
All Albino Wistar rats of around 170-200 gm, aged between 8-10 weeks, were used in the investigation of the analgesic property of the topical cream. Animals were obtained from the Committee for Control and Supervision of Experimental Animals (CCSEA) registration no. (273/PO/Re/S/2000/CCSEA, 24th November, 2000) further coordinated by Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024) animal house facility at SBSU Dehradun, Uttarakhand, India. The animals were kept in the rat cages in the animal house at room temperature and fed with standard amount of food and water, 6 hr before the experiment. 12 hr of light and dark cycle for 7 day was done in order to make them comfortable with the environment maintained with proper hygiene. The study was conducted as per the norms of CCSEA.
 
Preparation of the experimental plant
 
The seeds of the selected plants were collected, thoroughly cleaned and dried at an appropriate temperature of 40°C for 10 day to remove moisture content. The dried seeds 200 grams each were then finely powdered using a mechanical grinder. The powdered material was subjected to Soxhlet extraction using petroleum ether (300 ml; temperature maintained in between 60-80°C for every 04 cycles each hour for 10 hours duration for both the plant materials separately) as the solvent, which is effective in extracting lipophilic compounds such as fats and oils. Upon completion of the extraction process, the solvent was removed from the extract using a rotary evaporator (rotavapor) under reduced pressure. The obtained seed oil was subsequently used for the preparation of the topical formulation. 
       
Yield: 68 grams (34%) (Moringa oleifera) and 102 grams (51%) (Celastrus paniculatus) (Fig 1).

Fig 1: a) Seed of Celastrus paniculatus b) Seeds of Moringa oleifera c) Seed oil extracted from seeds of Celastrus paniculatus and Moringa oleifera.


 
Standardization of Moringa oleifera seed oil
 
The standardization of Moringa oleifera seed oil (Ben oil) was conducted to ensure its purity and high oleic acid content. The organoleptic evaluation confirmed a pale yellow, odorless liquid with a characteristic bland taste. Physicochemical parameters were determined, including specific gravity (0.900-0.915), refractive index (1.465-1.470), acid value (£2.0 mg KOH/g), iodine value (65-72 g /100g) and saponification value (185-195 mg KOH/g) (Anwar and Bhanger, 2003).
 
Standardization of Celastrus paniculatus seed oil
 
Celastrus paniculatus seed oil (Malkanguni oil) was standardized based on its unique sesquiterpene and alkaloidal markers. The oil appeared as a dark reddish-orange, viscous liquid with a pungent odor and an acrid taste. Physicochemical parameters were determined, including specific gravity (0.940-0.960), refractive index (1.475-1.490) and a significantly higher unsaponifiable matter (typically 3-5%) compared to edible oils, which contains the bioactive alkaloids celastrine and paniculatine (Sahu et al., 2020).
       
These physicochemical parameters provide preliminary standardization information as shown in Table 1.

Table 1: Summary for standardization of Moringa oleifera and Celastrus paniculatus seed oil.


 
Preparation and composition of the combined herbal cream
 
The herbal cream was prepared using the fusion method, involving the separate preparation of aqueous and oil phases. The aqueous phase was composed of distilled water (10 mL), propylene glycol (1.5 g) as a humectant and methyl paraben (0.1 g) as a preservative, with borax (0.1 g) added as an emulsifying agent. This mixture was heated until all components were completely solubilized. Simultaneously, the oil phase, consisting of beeswax (1.3 g) and liquid paraffin (2 mL), was heated until a uniform molten state was achieved. The aqueous phase was then gradually incorporated into the oil phase under continuous agitation using a laboratory stirrer to form a stable cream base.
       
To prepare the active formulations, the extracted combined oil blend (Moringa oleifera and Celastrus paniculatus) was incorporated into the pre-formed base to achieve final concentrations of 1%, 2% and 3% (w/w) (Fig 2). The pH of each formulation was monitored and adjusted using suitable acidifying or alkalizing agents to maintain a physiologically compatible range for topical application. The resulting creams were stirred until a homogenous consistency was obtained and stored for further analgesic evaluation. Quantitative Composition (Per Batch) is shown in Table 2.

Table 2: Quantitative composition (Per batch).



Fig 2: Representing various concentration of topical herbal formulation (1%, 2% and 3%).


 
Animal grouping
 
Twenty five healthy adult Wistar albino rats of either sex, weighing around 170 and 200 g, were housed under standard laboratory conditions (12 hrs light/dark cycle, temperature 25±2°C and relative humidity 50-60%) fed with standard amount of food and water, 6 hr before the experiment. The animals were divided into five groups, each group comprising of five rats (20 males and 05 females), (Sarwa et al., 2015; Kumar et al., 2009; Dwivedi et al., 2013).
 
Group 1: Control, i.e. one without any treatment.
 
Group 2: Standard, i.e. application of the Diclofenac 1.16% (100 mg).
 
Group 3: Test group, i.e. application of the formulated 1% of the seed oil cream (100 mg).
 
Group 4: Test group, i.e. application of the formulated 2% of the seed oil cream (100 mg).
 
Group 5: Test group, i.e. application of the formulated 3% of the seed oil cream (100 mg).
 
Physicochemical characterization of the formulated cream
 
The combined oil phase was prepared using Moringa oleiferaand Celastrus paniculatus seed oils in a 1:1 ratio by weight and this ratio was maintained for the 1%, 2% and 3% formulations (Table 2) and was subjected to rigorous physicochemical evaluation to ensure quality, stability and safety for topical application. The concentration of the total oil blend as well as the corresponding quantity of each individual oil would correspond to:
⮚1% total oil blend = 0.5% Moringa oleiferaoil + 0.5% Celastrus paniculatus oil.
⮚2% total oil blend = 1.0% Moringa oleiferaoil + 1.0% Celastrus paniculatus oil.
⮚3% total oil blend = 1.5% Moringa oleiferaoil + 1.5% Celastrus paniculatus oil.
 
Organoleptic evaluation and texture
 
The formulations were visually inspected for appearance (color and consistency) and evaluated for texture by manual application. The parameters assessed included smoothness, oiliness and the absence of coarse particles, ensuring a professional pharmaceutical aesthetic and user compliance.
 
Spreadability
 
Spreadability was evaluated to assess the ease of application and uniform distribution of the cream formulation over the intended application area. The test was performed using the two-glass-slide method. A measured quantity of formulation was placed between two glass slides and a standardized weight of 20 g was applied to the upper slide. The time required for the slides to separate over a specified distance was recorded.
       
Spreadability was calculated using the relationship:

 
Where,
S= Spreadability (g·cm/s).
M= The weight applied to the upper slide (20 g).
L= The length/distance of slide movement (5 cm).
T= The time required for separation (s).
       
The formulation showed a spreadability value of 29.6 g·cm/s, with a mean separation time of 3.37 s. These observations indicate that the formulation could be readily distributed over the application area.
 
pH measurement
 
The pH of the formulation was determined using a calibrated digital pH meter. A suitable quantity of the formulation was dispersed in distilled water before measurement and the pH was recorded after stabilization of the instrument reading. The pH of the formulations was found to be in the range of 5.5-5.8.
       
The pH measurement was used as a basic physicochemical characterization parameter relevant to topical application. The observed values were considered appropriate for the intended topical application; however, pH alone does not establish the absence of skin irritation or dermatological safety.
 
Rancidity and stability analysis
 
The rancidity of the oil within the formulation was monitored to assess oxidative degradation when exposed to environmental factors such as light and air. This parameter serves as a critical indicator of the shelf life and chemical stability of the bioactive lipid constituents.
       
The short-term stability of the formulation was evaluated by monitoring its observable physical characteristics under the specified experimental conditions. The formulation was examined for changes in appearance, colour, odour, consistency, phase separation and visible signs of deterioration during the observation period.
       
The stability assessment was therefore considered a short-term physical stability assessment. Because no validated chemical assay of the active constituents or degradation products was performed, the results do not establish long-term chemical stability, oxidative stability, or shelf life of the formulation.
 
Washability and absorbability
 
Washability was assessed qualitatively by applying a measured quantity of the cream formulation to the skin and subsequently evaluating the ease with which the formulation could be removed using water. The observation was recorded according to the ease of removal and the amount of visible residue remaining after washing.
       
Absorbability was assessed as a qualitative formulation property based on the apparent disappearance of the applied cream from the skin surface following topical application. This assessment was intended to characterize the handling and application characteristics of the formulation and was not used as a measure of dermal penetration or bioavailability.
       
The apparent absorption of the formulation into the skin cannot be equated with penetration of its constituents across the stratum corneum. Since no franz diffusion-cell study, ex vivo skin permeation experiment, skin-deposition analysis, or pharmacokinetic assessment was performed, the present study does not establish dermal penetration, tissue distribution, or bioavailability of the active constituents.
 
Safety profile: Patch test
 
A preliminary patch test was conducted to assess the short-term local tolerability of the topical herbal formulation following dermal application. The formulation was applied topically to the designated skin site of the experimental animal in the quantity used for the original safety assessment. The treated site was observed for visible signs of local irritation, including erythema (redness), Edema and other apparent skin reactions during the observation period. The treated site was examined following application and again at 24 h after treatment. The presence or absence of visible erythema, Edema, or redness was recorded. The formulation produced no visibly detectable Edema, erythema, or redness after 24 h and the observed irritation score was 0 under the scoring procedure used in the original assessment (Fig 3).

Fig 3: Patch test.


 
Pharmacological evaluation
 
Eddy’s hot plate method (Thermal analgesia)
 
The centrally acting analgesic potential of the combined herbal formulations was evaluated using Eddy’s hot plate method. This model assesses the reaction time of rats to thermal stress, which serves as an indicator of pain threshold elevation.
 
Protocol
 
Five groups of five albino rats each were utilized for the study. The temperature of the caliberated, Eddy’s hot plate was maintained at a constant 55±0.2°C.
 
• Group 1 (Negative control): Received no treatment to establish baseline latency.
 
• Group 2 (Positive control): Treated with 100 mg Diclofenac (1.16% w/w) (Manufactured by Ozone Pharmaceutical LTD., Batch no GD371422) via topical application with 30 seconds on the right hind paw. The first hot-plate measurement was performed 30 min after topical administration.
 
• Groups 3, 4 and 5 (Test groups): Treated with the 100 mg of formulated herbal cream at concentrations of 1%, 2% and 3% (w/w), respectively, applied topically same as group 2 animals, (Fig 4).

Fig 4: Analgesic activity using hot-plate test method.


       
The reaction time, defined as the latency period for the animal to exhibit behaviours such as paw licking, jumping, or shaking, was recorded at intervals of 30, 60, 90 and 120 minutes post-application. To prevent tissue damage, a cut-off time of 15 seconds was maintained. The percentage inhibition of the pain response was calculated using the following formula:


The complete experiment was designed in accordance with previously reported methods (Sarwa et al., 2015; Kumar et al., 2009; Dwivedi et al., 2013).
 
Carrageenan-induced hind paw edema (Anti-inflammatory activity)
 
The anti-inflammatory efficacy was assessed using the carrageenan-induced paw edema model, which represents the acute phase of inflammation.
 
Protocol
 
Five groups of five animals each were utilized for the study. Acute inflammation was induced via a sub-plantar injection (Levocarnitine by Akums Drugs and Pharmaceuticals Ltd. Batch no CAAD0006) of 0.1 mL of 1% sterile lambda carrageenan in saline into the right hind paw of each rat.
 
•  Pre-treatment: Sixty minutes prior to the carrageenan challenge, the test groups (Groups 3-5) received 100 mg of the prepared herbal formulations (1%, 2% and 3%).
•  Reference standard: Group 2 was treated with 100 mg of Diclofenac (1.16% w/w) cream as the standard reference drug.
 
• Control: Group 1 received the cream base without active oils.
     
The degree of inflammation was quantified by measuring the paw volume using a digital plethysmometer (Ugo Basile) at 30, 60, 90 and 120 minutes following carrageenan injection. The paw edema volume (change in paw volume) was calculated as the difference between the volume of the carrageenan-injected right hind paw and that of the non-injected left hind paw at each time point. The anti-inflammatory activity was expressed as the percentage inhibition of paw edema in the treatment groups compared with the control group, calculated using the following equation:
 

 
Ethical approval and compliance
 
The experimental protocol was submitted to and approved by Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024). All procedures were conducted in strict accordance with the guidelines provided by the Institutional Animal Ethics Committee.
 
Animal housing and management
 
Wistar albino rats of either sex, weighing between 170-200 g, were utilized for the study. The animals were housed in polypropylene cages with sterile husk bedding in a controlled environment. The housing conditions were maintained at a temperature of 25±2°C and a relative humidity of 55±5%, under a regulated 12-hour light/dark cycle. The rats were fed with standard amount of food and water, 6 hr before the experiment. Prior to the commencement of the experiments, the animals were acclimatized to the laboratory conditions for a period of seven days to eliminate stress-induced physiological variations.
 
Dose justification
 
The combined herbal formulations were prepared at concentrations of 1%, 2% and 3% (w/w) to evaluate the pharmacological activity of different concentrations of the formulation. These concentrations were incorporated into the cream base to facilitate topical application and uniform distribution of the combined Moringa oleifera and Celastrus paniculatus seed oils. The selected concentration range was subsequently evaluated for analgesic and anti-inflammatory activity under the experimental conditions of the present study.
The formulated herbal cream exhibited desirable physical characteristics. The spreadability was 29.6 g cm/sec, with a spreading time of 3.37 s. The formulation showed a semi-solid consistency, smooth texture and faint yellow colour. The pH of the formulation ranged from 5.5 to 5.8. During the one-month observation period, the formulation showed no visible phase separation or appreciable changes in texture or appearance. No observable rancidity was detected under the conditions examined, indicating short-term physical stability during the study period. However, chemical stability was not assessed using validated stability-indicating assays.
       
Following topical application, no observable edema, erythema, or redness was detected during the 24-hour observation period and the recorded irritation score was zero. The formulations containing up to 3% herbal blend therefore showed no observable signs of skin irritation under the conditions of the present study (Fig 3). These findings represent a preliminary acute tolerability assessment and do not establish long-term dermal safety.
       
In the analgesic activity study, the control group showed comparatively low response values throughout the experimental period, increasing only slightly from 3.72±0.64 at 30 min to 4.88±0.70 at 120 min. In contrast, treatment with standard diclofenac markedly increased the response from 8.12±0.37 at 30 min to 13.52±1.94 at 120 min (P<0.01), demonstrating the expected analgesic effect of the standard drug.
       
The 1% formulation produced a gradual increase in response from 5.50±1.19 at 30 min to 10.17±2.01 at 120 min. However, these changes were not statistically significant compared with the control group at the tested time points. This indicates that the lowest concentration of the formulation produced a measurable but comparatively weak analgesic response under the experimental conditions.
       
A pronounced response was observed with the 2% formulation. The values increased from 8.10±1.03 at 30 min to 13.30±1.59 at 120 min and were statistically significant (P<0.01) compared with the control group. Importantly, the response obtained with the 2% formulation remained very close to that of standard diclofenac throughout the observation period. At 30 min, the values were 8.10±1.03 and 8.12±0.37 for the 2% formulation and diclofenac, respectively, while at 120 min the corresponding values were 13.30±1.59 and 13.52±1.94. These findings suggest that the 2% formulation produced a strong analgesic effect under the conditions of the present experiment.
       
The 3% formulation also exhibited significant analgesic activity (P<0.05), with the response progressively increasing from 7.77±1.37 at 30 min to 13.46±1.33 at 120 min. The effect became particularly prominent at the later observation periods, reaching a response at 120 min that was numerically very close to standard diclofenac. Thus, both the 2% and 3% formulations demonstrated considerable analgesic potential, although the 2% formulation showed the more consistently significant response according to the present statistical analysis (Table 3).

Table 3: Analgesic effect of the formulation by hot plate method.


       
The progressive increase in response with time observed for the active formulations indicates that their analgesic effect developed gradually and was sustained throughout the 120-min observation period. Overall, the findings suggest that increasing the formulation concentration from 1% to 2% substantially improved analgesic activity. Increasing the concentration further to 3% did not produce a consistently greater effect than the 2% formulation, suggesting that the pharmacological response may approach a plateau around the 2% concentration (Fig 5).

Fig 5: Analgesic effect of formulation from Moringa oleifera and Celastrus paniculatus seed oil by using eddy’s hot plate method.


       
The anti-inflammatory study showed a similar treatment-related pattern. The control group maintained relatively high values throughout the experiment, decreasing from 0.61±0.10 at 30 min to 0.50±0.02 at 120 min. In contrast, standard diclofenac produced a marked and progressive reduction, from 0.36±0.02 at 30 min to 0.24±0.02 at 120 min (P<0.01), confirming its expected anti-inflammatory activity.
       
The 1% formulation produced values of 0.56±0.02, 0.50±0.02, 0.45±0.04 and 0.40±0.04 at 30, 60, 90 and 120 min, respectively. Although a progressive reduction was evident, the effect did not reach statistical significance compared with the control group. This suggests that the 1% concentration was insufficient to produce a strong anti-inflammatory response under the experimental conditions.
       
The 2% formulation produced a considerably greater reduction, with values declining from 0.37±0.02 at 30 min to 0.24±0.02 at 120 min (P<0.01). The values were remarkably close to those obtained with standard diclofenac throughout the experiment. At 30 min, the values were 0.37±0.02 and 0.36±0.02 for the 2% formulation and standard diclofenac, respectively, whereas at 120 min both groups showed a mean value of 0.24. These findings demonstrate that the 2% formulation exerted a strong anti-inflammatory effect in this experimental model.
       
Similarly, the 3% formulation significantly reduced the measured response (P<0.05), from 0.42±0.03 at 30 min to 0.25±0.03 at 120 min. Its activity became increasingly pronounced with time and by 120 min its mean response was close to both the 2% formulation and standard diclofenac. The progressive reduction observed with the active formulations suggests sustained inhibition of the inflammatory response during the experimental period (Table 4).

Table 4: Anti-inflammatoty effect of formulation-carrageenan-induced method.


       
Taken together, the results demonstrate that the developed formulation possesses both analgesic and anti-inflammatory activities. The 1% formulation showed relatively weak activity, whereas increasing the concentration to 2% produced a marked enhancement in both pharmacological responses. Although the 3% formulation was also effective, increasing the concentration from 2% to 3% did not result in a proportional improvement in activity. In several observations, the 2% formulation produced responses essentially comparable to those of the 3% formulation and numerically close to standard diclofenac (Fig 6).

Fig 6: Anti-inflammatory effect of formulation from Moringa oleifera and Celastrus paniculatus seed oil by using carrageenan induced paw edema method.


       
Therefore, among the tested concentrations, the 2% formulation appears to provide the most favorable concentration-response relationship. However, the apparent similarity between the 2% formulation and standard diclofenac should be interpreted as numerical comparability rather than statistical equivalence, because the Dunnett’s analysis used in the present study compares each treatment group with the control and does not directly establish equivalence or non-inferiority between the formulation and diclofenac. Overall, these findings support further investigation of the 2% formulation as a potentially effective concentration for analgesic and anti-inflammatory activity.
       
The present study evaluated the analgesic and anti-inflammatory potential of a topical herbal cream containing Moringa oleifera and Celastrus paniculatus seed oils. The formulation showed satisfactory physical characteristics and short-term stability, with no observable signs of skin irritation during the study period. The present study evaluated the pharmacological activity of the developed formulations at three different concentrations (1%, 2% and 3%) in comparison with the control and standard diclofenac (1.16%). The results demonstrated that the formulations produced concentration-dependent biological activity, with the 2% and 3% formulations showing substantially greater effects than the 1% formulation. Among the tested formulations, the 2% formulation exhibited an effect comparable to that of standard diclofenac at most of the observation periods.
       
Although previous studies have reported pharmacological activities of Moringa oleifera and Celastrus paniculatus, the present experiment did not include separate treatment groups for each individual oil. Therefore, synergistic, additive, or antagonistic interactions between the two oils cannot be conclusively established. The findings should consequently be considered preliminary evidence of the analgesic and anti-inflammatory potential of the combined formulation rather than proof of therapeutic efficacy.
The formulated herbal cream demonstrated satisfactory physical characteristics, short-term physical stability and no observable acute skin irritation under the conditions of the present study. The 2% and 3% formulations showed measurable analgesic and anti-inflammatory activity in the hot-plate and carrageenan-induced paw edema models, respectively, with the 2% formulation showing a notable response among the tested concentrations. However, the study does not establish synergistic interaction between the two oils, specific mechanisms of action, long-term dermal safety, or clinical therapeutic efficacy. Overall, the findings provide preliminary preclinical evidence supporting further investigation of the combined M. oleifera and C. paniculatus topical formulation.
The authors are thankful to the grant of Uttarakhand State Council for Science and Technology, Dehradun Uttarakhand UCOST- UCOST-RND/5/2024UCOST-DPT-26324. The authors also thank the School of Applied chemistry and Basic Sciences and School of Life Sciences, SBS University, for providing the space and facilities to carry out this research work.
 
Disclaimers
 
The views and conclusions expressed in this article are solely those of the authors and do not necessarily represent the views of their affiliated institutions. The authors are responsible for the accuracy and completeness of the information provided, but do not accept any liability for any direct or indirect losses resulting from the use of this content.
 
Informed consent
 
All animal procedures for experiments were in accordance with Committee of Experimental Animal care (273/PO/Re/S/2000/CCSEA, 24th November, 2000) and handling techniques were approved by the Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024).
The authors declare that there are no conflicts of interest regarding the publication of this article. No funding or sponsorship influenced the design of the study, data collection, analysis, decision to publish, or preparation of the manuscript.

  1. Abdul, H.M., Sarkhil, M.Z., Fayazuddin, M. and Ahmad, F. (2021). Peripheral analgesic activity of Moringa oleifera seeds- An experimental study. Asian Journal of Pharmacy and Pharmacology. 7(5): 200-203. 

  2. Abebe, W. (2002). Herbal medication: Potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics. 27(6): 391-401.

  3. Ahmad, F., Khan, R.A. and Rasheed, S. (1994). Preliminary screening of methanolic extracts of Celastrus paniculatus and Tecomella undulata for analgesic and anti-inflammatory activities. Journal of Ethnopharmacology. 42(3): 193- 198. https://doi.org/10.1016/0378-8741(94)90085.

  4. Anwar, F. and Bhanger, M.I. (2003). Analytical characterization of Moringa oleifera seed oil grown in temperate regions of Pakistan. Journal of Agricultural and Food Chemistry. 51(22): 6558-6563. https://doi.org/10.1021/jf0209894.

  5. Dwivedi, V. and Maurya, H. (2018). A comprehensive overview of Celastrus paniculatus seed oil intended for the management of human ailments. Indian Journal of Pharmaceutical and Biological Research. 6(2): 37-42.

  6. Dwivedi, V. and D’Souza, P. (2013). Antioxidant, analgesic and anti-inflammatory activities of the methanolic extract of Piper betle leaves. Avicenna Journal of Phytomedicine. 3(4): 325-334.

  7. Kanitta, J. and Wannee (2016). Moringa oleifera: A new challenge reducing heavy metal toxicity: A review. Indian Journal of Agricultural Research. 50(3): 199-205. doi: 10.18805/ijare.v0iOF.9361.

  8. Kulkarni, Y.A., Agarwal, S. and Garud, M.S. (2015). Effect of jyotishmati (Celastrus paniculatus) seeds in animal models of pain and inflammation. Journal of Ayurveda and Integrative Medicine. 6(2): 82-88. https://doi.org/10.4103/0975-9476.146540.

  9. Kumar, A., Panghal, S., Mallapur, S.S., Kumar, M., Ram, V. and Singh, B.K. (2009). Antiinflammatory activity of Piper longum fruit oil. Indian Journal of Pharmaceutical Sciences. 71(4): 454-456. https://doi.org/10.4103/0250-474X.57300. 

  10. Nagpal, K., Garg, M., Arora, D., Dubey, A. and Grewal, A.S. (2022). An extensive review on phytochemistry and pharmacological activities of Indian medicinal plant Celastrus paniculatus Willd. Phytotherapy Research. 36(5): 1930-1951. https://doi.org/10.1002/ptr.7424.

  11. Rathaur, A. (2024). Development of chhana spread by incorporating moringa (Moringa oleifera L.) leaves extract as a source of antioxidants and phenolics. Asian Journal of Dairy and Food Research. 43(1): 142-147. doi: 10.18805/ajdfr.DR-2082.

  12. Sarwa, K.K., Mazumder, B., Rudrapal, M. and Verma, V.K. (2015). Potential of capsaicin-loaded transfersomes in arthritic rats. Drug Delivery. 22(5): 638-646. https://doi.org/10.3109/10717544.2013.871601. 

  13. Sahu, L., Joshi, P.K., Rout, O.P. and Sahu, A. (2020). Phytochemical evaluation of Celastrus paniculatus seed oil extracted by a method used by ‘Uraanv’ tribe of Chhattisgarh. Journal of Ayurveda and Integrated Medical Sciences. 5(2): 57-65. https://doi.org/10.21760/jaims.5.2.9.

  14. Ugwuoke, C.U., Eze, G.E., Mgbenka, R.N., Omeje, B.A., Osinem, E.C. and Machebe, N.S. (2020). Effects of dietary intake of Moringa oleifera leaf meal on the growth performance of pullet chicks. Agricultural Science Digest. 40(2): 194- 198. doi: 10.18805/ag.D-189.

Analgesic and Anti-inflammatory Efficacy of a Combined Herbal Formulation Containing Moringa oleifera and Celastrus paniculatus Seed Oils

N
Neetu Pandey1,*
S
Santosh K. Karn2
R
Ritika Mehra1
P
Pradyumna Ghosal1
1Department of Applied Chemistry and Basic Sciences, School of Basic and Life Sciences, Sardar Bhagwan Singh University, Dehradun-248 019, Uttrakhand, India.
2Department of Biochemistry and Biotechnology, School of Basic and Life Sciences, Sardar Bhagwan Singh University, Dehradun-248 019, Uttrakhand, India.

Background: Herbal seed oils have attracted interest as potential sources of bioactive compounds with analgesic and anti-inflammatory properties. Moringa oleifera and Celastrus paniculatus have individually been investigated for pharmacological activities; however, the activity of a topical formulation containing their seed oils warrants further experimental evaluation. The present study evaluated the preliminary analgesic and anti-inflammatory activity and short-term topical tolerability of formulations containing combined Moringa oleifera and Celastrus paniculatus seed oils.

Methods: Topical formulations containing 1%, 2% and 3% combined seed oils were evaluated in experimental animal models of nociception and inflammation. Diclofenac was included as a reference treatment. Analgesic activity was assessed using the hot-plate test, while anti-inflammatory activity was evaluated using carrageenan-induced paw edema. Basic physicochemical characteristics and short-term topical tolerability were also assessed.

Result: The combined seed-oil formulations demonstrated measurable analgesic and anti-inflammatory activity compared with the control treatment, with the magnitude of response varying according to formulation concentration and observation time. Among the concentrations tested, the 2% formulation showed the strongest overall response in the experimental models. However, responses were not consistently greater at 3%, indicating that increasing formulation concentration did not necessarily result in a proportional increase in activity. The formulation did not produce observable acute local irritation under the conditions evaluated.

Pain is one of the most common symptoms encountered in clinical practice and has traditionally been managed using medicinal plants and herbal preparations. Although conventional analgesic and non-steroidal anti-inflammatory drugs (NSAID), are widely used, their prolonged use may be associated with adverse effects, creating continued interest in safer and potentially effective plant-based alternatives (Abdul et al., 2021). Among medicinal plants, Moringa oleifera and Celastrus paniculatus have attracted attention because of their reported analgesic and anti-inflammatory properties (Abebe, 2002).
       
Moringa oleifera
(Moringaceae) is a medicinal plant rich in biologically active constituents, including alkaloids, glycosides, phenolic compounds, saponins and tannins (Kanitta and Wannee, 2016, Ugwuoke et al., 2020, Rathaur, 2024). Previous studies have reported its analgesic and anti-inflammatory potential, suggesting that its phytochemical constituents may contribute to modulation of pain and inflammation (Dwivedi and Maurya, 2018). Similarly, Celastrus paniculatus is a medicinal shrub whose seeds and seed oil have traditionally been used in Ayurveda for various disorders, including applications related to neurological and pain-associated conditions (Kulkarni et al., 2015). Phytochemical investigations have identified alkaloids and other bioactive constituents in Celastrus paniculatus, while experimental studies have reported analgesic and anti-inflammatory effects of its extracts (Ahmad et al., 1994; Nagpal et al., 2022).
       
The pharmacological activities reported for these two botanically distinct plants provide a scientific basis for investigating their use together in a topical formulation. However, the rationale for their combination should be distinguished from a claim of pharmacological synergy. Although both plants have individually demonstrated analgesic and/or anti-inflammatory potential, the present study was not designed to establish whether their interaction is synergistic, additive, antagonistic, or simply reflects the combined effects of their constituents. Demonstration of synergy would require appropriate individual-oil comparator groups and a predefined method for assessing drug interaction.
       
Topical delivery of plant-derived oils may provide a convenient approach for local application while avoiding some limitations associated with systemic administration. Despite reports on the individual biological activities of Moringa oleifera and Celastrus paniculatus, limited experimental information is available on their combined seed oils incorporated into a topical cream and evaluated for analgesic and anti-inflammatory activity in vivo. Therefore, the present study focuses on the development and preliminary evaluation of such a combined formulation rather than claiming a synergistic effect.
       
Accordingly, the objective of the present study was to formulate topical creams containing combined Moringa oleifera and Celastrus paniculatus seed oils at different concentrations and to evaluate their preliminary analgesic and anti-inflammatory activities using the hot-plate test and carrageenan-induced paw-Edema models in Wistar albino rats.
Drugs and chemicals
 
All chemicals and reagents used in the present study were of analytical grade. Methyl paraben, liquid paraffin, polyethene glycol (PEG), beeswax, borax, petroleum ether, citric acid and distilled water were utilised in the experimental work. All the chemicals were procured from the laboratory of Sardar Bhagwan Singh University, Balawala, Dehradun, India and were used without further purification. All reagents were stored under appropriate conditions as per standard laboratory protocols to ensure stability and reliability of results. All experimental work was carried out in the laboratory of Sardar Bhagwan Singh University, Balawala, Dehradun, India in the year between 2025-2026.
 
Collection and identification
 
The plant seeds of Moringa oleifera were obtained from the campus of Sardar Bhagwan Singh University (SBSU), Dehradun, India and Celastrus paniculatus were obtained from the Swami Ram Teerth, (SRT) campus Botanical Garden, Badshahtithaul Tehri Garwal, Uttarakhand, India. The authentication of the given seeds plants was done through Botanical Survey India, (BSI) Dehradun, Uttarakhand, India and ICFRE-Forest Research Institute  Dehradun, Uttarakhand, India. Authentication number for Moringa oleifera was BSI/NRC.Herb(Ident.)/2024-25/646 and Authentication number for Celastrus paniculatus was 790/Dis./2026-27/Syst.Bot./Rev.Gen./4-5.
 
Animals
 
All Albino Wistar rats of around 170-200 gm, aged between 8-10 weeks, were used in the investigation of the analgesic property of the topical cream. Animals were obtained from the Committee for Control and Supervision of Experimental Animals (CCSEA) registration no. (273/PO/Re/S/2000/CCSEA, 24th November, 2000) further coordinated by Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024) animal house facility at SBSU Dehradun, Uttarakhand, India. The animals were kept in the rat cages in the animal house at room temperature and fed with standard amount of food and water, 6 hr before the experiment. 12 hr of light and dark cycle for 7 day was done in order to make them comfortable with the environment maintained with proper hygiene. The study was conducted as per the norms of CCSEA.
 
Preparation of the experimental plant
 
The seeds of the selected plants were collected, thoroughly cleaned and dried at an appropriate temperature of 40°C for 10 day to remove moisture content. The dried seeds 200 grams each were then finely powdered using a mechanical grinder. The powdered material was subjected to Soxhlet extraction using petroleum ether (300 ml; temperature maintained in between 60-80°C for every 04 cycles each hour for 10 hours duration for both the plant materials separately) as the solvent, which is effective in extracting lipophilic compounds such as fats and oils. Upon completion of the extraction process, the solvent was removed from the extract using a rotary evaporator (rotavapor) under reduced pressure. The obtained seed oil was subsequently used for the preparation of the topical formulation. 
       
Yield: 68 grams (34%) (Moringa oleifera) and 102 grams (51%) (Celastrus paniculatus) (Fig 1).

Fig 1: a) Seed of Celastrus paniculatus b) Seeds of Moringa oleifera c) Seed oil extracted from seeds of Celastrus paniculatus and Moringa oleifera.


 
Standardization of Moringa oleifera seed oil
 
The standardization of Moringa oleifera seed oil (Ben oil) was conducted to ensure its purity and high oleic acid content. The organoleptic evaluation confirmed a pale yellow, odorless liquid with a characteristic bland taste. Physicochemical parameters were determined, including specific gravity (0.900-0.915), refractive index (1.465-1.470), acid value (£2.0 mg KOH/g), iodine value (65-72 g /100g) and saponification value (185-195 mg KOH/g) (Anwar and Bhanger, 2003).
 
Standardization of Celastrus paniculatus seed oil
 
Celastrus paniculatus seed oil (Malkanguni oil) was standardized based on its unique sesquiterpene and alkaloidal markers. The oil appeared as a dark reddish-orange, viscous liquid with a pungent odor and an acrid taste. Physicochemical parameters were determined, including specific gravity (0.940-0.960), refractive index (1.475-1.490) and a significantly higher unsaponifiable matter (typically 3-5%) compared to edible oils, which contains the bioactive alkaloids celastrine and paniculatine (Sahu et al., 2020).
       
These physicochemical parameters provide preliminary standardization information as shown in Table 1.

Table 1: Summary for standardization of Moringa oleifera and Celastrus paniculatus seed oil.


 
Preparation and composition of the combined herbal cream
 
The herbal cream was prepared using the fusion method, involving the separate preparation of aqueous and oil phases. The aqueous phase was composed of distilled water (10 mL), propylene glycol (1.5 g) as a humectant and methyl paraben (0.1 g) as a preservative, with borax (0.1 g) added as an emulsifying agent. This mixture was heated until all components were completely solubilized. Simultaneously, the oil phase, consisting of beeswax (1.3 g) and liquid paraffin (2 mL), was heated until a uniform molten state was achieved. The aqueous phase was then gradually incorporated into the oil phase under continuous agitation using a laboratory stirrer to form a stable cream base.
       
To prepare the active formulations, the extracted combined oil blend (Moringa oleifera and Celastrus paniculatus) was incorporated into the pre-formed base to achieve final concentrations of 1%, 2% and 3% (w/w) (Fig 2). The pH of each formulation was monitored and adjusted using suitable acidifying or alkalizing agents to maintain a physiologically compatible range for topical application. The resulting creams were stirred until a homogenous consistency was obtained and stored for further analgesic evaluation. Quantitative Composition (Per Batch) is shown in Table 2.

Table 2: Quantitative composition (Per batch).



Fig 2: Representing various concentration of topical herbal formulation (1%, 2% and 3%).


 
Animal grouping
 
Twenty five healthy adult Wistar albino rats of either sex, weighing around 170 and 200 g, were housed under standard laboratory conditions (12 hrs light/dark cycle, temperature 25±2°C and relative humidity 50-60%) fed with standard amount of food and water, 6 hr before the experiment. The animals were divided into five groups, each group comprising of five rats (20 males and 05 females), (Sarwa et al., 2015; Kumar et al., 2009; Dwivedi et al., 2013).
 
Group 1: Control, i.e. one without any treatment.
 
Group 2: Standard, i.e. application of the Diclofenac 1.16% (100 mg).
 
Group 3: Test group, i.e. application of the formulated 1% of the seed oil cream (100 mg).
 
Group 4: Test group, i.e. application of the formulated 2% of the seed oil cream (100 mg).
 
Group 5: Test group, i.e. application of the formulated 3% of the seed oil cream (100 mg).
 
Physicochemical characterization of the formulated cream
 
The combined oil phase was prepared using Moringa oleiferaand Celastrus paniculatus seed oils in a 1:1 ratio by weight and this ratio was maintained for the 1%, 2% and 3% formulations (Table 2) and was subjected to rigorous physicochemical evaluation to ensure quality, stability and safety for topical application. The concentration of the total oil blend as well as the corresponding quantity of each individual oil would correspond to:
⮚1% total oil blend = 0.5% Moringa oleiferaoil + 0.5% Celastrus paniculatus oil.
⮚2% total oil blend = 1.0% Moringa oleiferaoil + 1.0% Celastrus paniculatus oil.
⮚3% total oil blend = 1.5% Moringa oleiferaoil + 1.5% Celastrus paniculatus oil.
 
Organoleptic evaluation and texture
 
The formulations were visually inspected for appearance (color and consistency) and evaluated for texture by manual application. The parameters assessed included smoothness, oiliness and the absence of coarse particles, ensuring a professional pharmaceutical aesthetic and user compliance.
 
Spreadability
 
Spreadability was evaluated to assess the ease of application and uniform distribution of the cream formulation over the intended application area. The test was performed using the two-glass-slide method. A measured quantity of formulation was placed between two glass slides and a standardized weight of 20 g was applied to the upper slide. The time required for the slides to separate over a specified distance was recorded.
       
Spreadability was calculated using the relationship:

 
Where,
S= Spreadability (g·cm/s).
M= The weight applied to the upper slide (20 g).
L= The length/distance of slide movement (5 cm).
T= The time required for separation (s).
       
The formulation showed a spreadability value of 29.6 g·cm/s, with a mean separation time of 3.37 s. These observations indicate that the formulation could be readily distributed over the application area.
 
pH measurement
 
The pH of the formulation was determined using a calibrated digital pH meter. A suitable quantity of the formulation was dispersed in distilled water before measurement and the pH was recorded after stabilization of the instrument reading. The pH of the formulations was found to be in the range of 5.5-5.8.
       
The pH measurement was used as a basic physicochemical characterization parameter relevant to topical application. The observed values were considered appropriate for the intended topical application; however, pH alone does not establish the absence of skin irritation or dermatological safety.
 
Rancidity and stability analysis
 
The rancidity of the oil within the formulation was monitored to assess oxidative degradation when exposed to environmental factors such as light and air. This parameter serves as a critical indicator of the shelf life and chemical stability of the bioactive lipid constituents.
       
The short-term stability of the formulation was evaluated by monitoring its observable physical characteristics under the specified experimental conditions. The formulation was examined for changes in appearance, colour, odour, consistency, phase separation and visible signs of deterioration during the observation period.
       
The stability assessment was therefore considered a short-term physical stability assessment. Because no validated chemical assay of the active constituents or degradation products was performed, the results do not establish long-term chemical stability, oxidative stability, or shelf life of the formulation.
 
Washability and absorbability
 
Washability was assessed qualitatively by applying a measured quantity of the cream formulation to the skin and subsequently evaluating the ease with which the formulation could be removed using water. The observation was recorded according to the ease of removal and the amount of visible residue remaining after washing.
       
Absorbability was assessed as a qualitative formulation property based on the apparent disappearance of the applied cream from the skin surface following topical application. This assessment was intended to characterize the handling and application characteristics of the formulation and was not used as a measure of dermal penetration or bioavailability.
       
The apparent absorption of the formulation into the skin cannot be equated with penetration of its constituents across the stratum corneum. Since no franz diffusion-cell study, ex vivo skin permeation experiment, skin-deposition analysis, or pharmacokinetic assessment was performed, the present study does not establish dermal penetration, tissue distribution, or bioavailability of the active constituents.
 
Safety profile: Patch test
 
A preliminary patch test was conducted to assess the short-term local tolerability of the topical herbal formulation following dermal application. The formulation was applied topically to the designated skin site of the experimental animal in the quantity used for the original safety assessment. The treated site was observed for visible signs of local irritation, including erythema (redness), Edema and other apparent skin reactions during the observation period. The treated site was examined following application and again at 24 h after treatment. The presence or absence of visible erythema, Edema, or redness was recorded. The formulation produced no visibly detectable Edema, erythema, or redness after 24 h and the observed irritation score was 0 under the scoring procedure used in the original assessment (Fig 3).

Fig 3: Patch test.


 
Pharmacological evaluation
 
Eddy’s hot plate method (Thermal analgesia)
 
The centrally acting analgesic potential of the combined herbal formulations was evaluated using Eddy’s hot plate method. This model assesses the reaction time of rats to thermal stress, which serves as an indicator of pain threshold elevation.
 
Protocol
 
Five groups of five albino rats each were utilized for the study. The temperature of the caliberated, Eddy’s hot plate was maintained at a constant 55±0.2°C.
 
• Group 1 (Negative control): Received no treatment to establish baseline latency.
 
• Group 2 (Positive control): Treated with 100 mg Diclofenac (1.16% w/w) (Manufactured by Ozone Pharmaceutical LTD., Batch no GD371422) via topical application with 30 seconds on the right hind paw. The first hot-plate measurement was performed 30 min after topical administration.
 
• Groups 3, 4 and 5 (Test groups): Treated with the 100 mg of formulated herbal cream at concentrations of 1%, 2% and 3% (w/w), respectively, applied topically same as group 2 animals, (Fig 4).

Fig 4: Analgesic activity using hot-plate test method.


       
The reaction time, defined as the latency period for the animal to exhibit behaviours such as paw licking, jumping, or shaking, was recorded at intervals of 30, 60, 90 and 120 minutes post-application. To prevent tissue damage, a cut-off time of 15 seconds was maintained. The percentage inhibition of the pain response was calculated using the following formula:


The complete experiment was designed in accordance with previously reported methods (Sarwa et al., 2015; Kumar et al., 2009; Dwivedi et al., 2013).
 
Carrageenan-induced hind paw edema (Anti-inflammatory activity)
 
The anti-inflammatory efficacy was assessed using the carrageenan-induced paw edema model, which represents the acute phase of inflammation.
 
Protocol
 
Five groups of five animals each were utilized for the study. Acute inflammation was induced via a sub-plantar injection (Levocarnitine by Akums Drugs and Pharmaceuticals Ltd. Batch no CAAD0006) of 0.1 mL of 1% sterile lambda carrageenan in saline into the right hind paw of each rat.
 
•  Pre-treatment: Sixty minutes prior to the carrageenan challenge, the test groups (Groups 3-5) received 100 mg of the prepared herbal formulations (1%, 2% and 3%).
•  Reference standard: Group 2 was treated with 100 mg of Diclofenac (1.16% w/w) cream as the standard reference drug.
 
• Control: Group 1 received the cream base without active oils.
     
The degree of inflammation was quantified by measuring the paw volume using a digital plethysmometer (Ugo Basile) at 30, 60, 90 and 120 minutes following carrageenan injection. The paw edema volume (change in paw volume) was calculated as the difference between the volume of the carrageenan-injected right hind paw and that of the non-injected left hind paw at each time point. The anti-inflammatory activity was expressed as the percentage inhibition of paw edema in the treatment groups compared with the control group, calculated using the following equation:
 

 
Ethical approval and compliance
 
The experimental protocol was submitted to and approved by Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024). All procedures were conducted in strict accordance with the guidelines provided by the Institutional Animal Ethics Committee.
 
Animal housing and management
 
Wistar albino rats of either sex, weighing between 170-200 g, were utilized for the study. The animals were housed in polypropylene cages with sterile husk bedding in a controlled environment. The housing conditions were maintained at a temperature of 25±2°C and a relative humidity of 55±5%, under a regulated 12-hour light/dark cycle. The rats were fed with standard amount of food and water, 6 hr before the experiment. Prior to the commencement of the experiments, the animals were acclimatized to the laboratory conditions for a period of seven days to eliminate stress-induced physiological variations.
 
Dose justification
 
The combined herbal formulations were prepared at concentrations of 1%, 2% and 3% (w/w) to evaluate the pharmacological activity of different concentrations of the formulation. These concentrations were incorporated into the cream base to facilitate topical application and uniform distribution of the combined Moringa oleifera and Celastrus paniculatus seed oils. The selected concentration range was subsequently evaluated for analgesic and anti-inflammatory activity under the experimental conditions of the present study.
The formulated herbal cream exhibited desirable physical characteristics. The spreadability was 29.6 g cm/sec, with a spreading time of 3.37 s. The formulation showed a semi-solid consistency, smooth texture and faint yellow colour. The pH of the formulation ranged from 5.5 to 5.8. During the one-month observation period, the formulation showed no visible phase separation or appreciable changes in texture or appearance. No observable rancidity was detected under the conditions examined, indicating short-term physical stability during the study period. However, chemical stability was not assessed using validated stability-indicating assays.
       
Following topical application, no observable edema, erythema, or redness was detected during the 24-hour observation period and the recorded irritation score was zero. The formulations containing up to 3% herbal blend therefore showed no observable signs of skin irritation under the conditions of the present study (Fig 3). These findings represent a preliminary acute tolerability assessment and do not establish long-term dermal safety.
       
In the analgesic activity study, the control group showed comparatively low response values throughout the experimental period, increasing only slightly from 3.72±0.64 at 30 min to 4.88±0.70 at 120 min. In contrast, treatment with standard diclofenac markedly increased the response from 8.12±0.37 at 30 min to 13.52±1.94 at 120 min (P<0.01), demonstrating the expected analgesic effect of the standard drug.
       
The 1% formulation produced a gradual increase in response from 5.50±1.19 at 30 min to 10.17±2.01 at 120 min. However, these changes were not statistically significant compared with the control group at the tested time points. This indicates that the lowest concentration of the formulation produced a measurable but comparatively weak analgesic response under the experimental conditions.
       
A pronounced response was observed with the 2% formulation. The values increased from 8.10±1.03 at 30 min to 13.30±1.59 at 120 min and were statistically significant (P<0.01) compared with the control group. Importantly, the response obtained with the 2% formulation remained very close to that of standard diclofenac throughout the observation period. At 30 min, the values were 8.10±1.03 and 8.12±0.37 for the 2% formulation and diclofenac, respectively, while at 120 min the corresponding values were 13.30±1.59 and 13.52±1.94. These findings suggest that the 2% formulation produced a strong analgesic effect under the conditions of the present experiment.
       
The 3% formulation also exhibited significant analgesic activity (P<0.05), with the response progressively increasing from 7.77±1.37 at 30 min to 13.46±1.33 at 120 min. The effect became particularly prominent at the later observation periods, reaching a response at 120 min that was numerically very close to standard diclofenac. Thus, both the 2% and 3% formulations demonstrated considerable analgesic potential, although the 2% formulation showed the more consistently significant response according to the present statistical analysis (Table 3).

Table 3: Analgesic effect of the formulation by hot plate method.


       
The progressive increase in response with time observed for the active formulations indicates that their analgesic effect developed gradually and was sustained throughout the 120-min observation period. Overall, the findings suggest that increasing the formulation concentration from 1% to 2% substantially improved analgesic activity. Increasing the concentration further to 3% did not produce a consistently greater effect than the 2% formulation, suggesting that the pharmacological response may approach a plateau around the 2% concentration (Fig 5).

Fig 5: Analgesic effect of formulation from Moringa oleifera and Celastrus paniculatus seed oil by using eddy’s hot plate method.


       
The anti-inflammatory study showed a similar treatment-related pattern. The control group maintained relatively high values throughout the experiment, decreasing from 0.61±0.10 at 30 min to 0.50±0.02 at 120 min. In contrast, standard diclofenac produced a marked and progressive reduction, from 0.36±0.02 at 30 min to 0.24±0.02 at 120 min (P<0.01), confirming its expected anti-inflammatory activity.
       
The 1% formulation produced values of 0.56±0.02, 0.50±0.02, 0.45±0.04 and 0.40±0.04 at 30, 60, 90 and 120 min, respectively. Although a progressive reduction was evident, the effect did not reach statistical significance compared with the control group. This suggests that the 1% concentration was insufficient to produce a strong anti-inflammatory response under the experimental conditions.
       
The 2% formulation produced a considerably greater reduction, with values declining from 0.37±0.02 at 30 min to 0.24±0.02 at 120 min (P<0.01). The values were remarkably close to those obtained with standard diclofenac throughout the experiment. At 30 min, the values were 0.37±0.02 and 0.36±0.02 for the 2% formulation and standard diclofenac, respectively, whereas at 120 min both groups showed a mean value of 0.24. These findings demonstrate that the 2% formulation exerted a strong anti-inflammatory effect in this experimental model.
       
Similarly, the 3% formulation significantly reduced the measured response (P<0.05), from 0.42±0.03 at 30 min to 0.25±0.03 at 120 min. Its activity became increasingly pronounced with time and by 120 min its mean response was close to both the 2% formulation and standard diclofenac. The progressive reduction observed with the active formulations suggests sustained inhibition of the inflammatory response during the experimental period (Table 4).

Table 4: Anti-inflammatoty effect of formulation-carrageenan-induced method.


       
Taken together, the results demonstrate that the developed formulation possesses both analgesic and anti-inflammatory activities. The 1% formulation showed relatively weak activity, whereas increasing the concentration to 2% produced a marked enhancement in both pharmacological responses. Although the 3% formulation was also effective, increasing the concentration from 2% to 3% did not result in a proportional improvement in activity. In several observations, the 2% formulation produced responses essentially comparable to those of the 3% formulation and numerically close to standard diclofenac (Fig 6).

Fig 6: Anti-inflammatory effect of formulation from Moringa oleifera and Celastrus paniculatus seed oil by using carrageenan induced paw edema method.


       
Therefore, among the tested concentrations, the 2% formulation appears to provide the most favorable concentration-response relationship. However, the apparent similarity between the 2% formulation and standard diclofenac should be interpreted as numerical comparability rather than statistical equivalence, because the Dunnett’s analysis used in the present study compares each treatment group with the control and does not directly establish equivalence or non-inferiority between the formulation and diclofenac. Overall, these findings support further investigation of the 2% formulation as a potentially effective concentration for analgesic and anti-inflammatory activity.
       
The present study evaluated the analgesic and anti-inflammatory potential of a topical herbal cream containing Moringa oleifera and Celastrus paniculatus seed oils. The formulation showed satisfactory physical characteristics and short-term stability, with no observable signs of skin irritation during the study period. The present study evaluated the pharmacological activity of the developed formulations at three different concentrations (1%, 2% and 3%) in comparison with the control and standard diclofenac (1.16%). The results demonstrated that the formulations produced concentration-dependent biological activity, with the 2% and 3% formulations showing substantially greater effects than the 1% formulation. Among the tested formulations, the 2% formulation exhibited an effect comparable to that of standard diclofenac at most of the observation periods.
       
Although previous studies have reported pharmacological activities of Moringa oleifera and Celastrus paniculatus, the present experiment did not include separate treatment groups for each individual oil. Therefore, synergistic, additive, or antagonistic interactions between the two oils cannot be conclusively established. The findings should consequently be considered preliminary evidence of the analgesic and anti-inflammatory potential of the combined formulation rather than proof of therapeutic efficacy.
The formulated herbal cream demonstrated satisfactory physical characteristics, short-term physical stability and no observable acute skin irritation under the conditions of the present study. The 2% and 3% formulations showed measurable analgesic and anti-inflammatory activity in the hot-plate and carrageenan-induced paw edema models, respectively, with the 2% formulation showing a notable response among the tested concentrations. However, the study does not establish synergistic interaction between the two oils, specific mechanisms of action, long-term dermal safety, or clinical therapeutic efficacy. Overall, the findings provide preliminary preclinical evidence supporting further investigation of the combined M. oleifera and C. paniculatus topical formulation.
The authors are thankful to the grant of Uttarakhand State Council for Science and Technology, Dehradun Uttarakhand UCOST- UCOST-RND/5/2024UCOST-DPT-26324. The authors also thank the School of Applied chemistry and Basic Sciences and School of Life Sciences, SBS University, for providing the space and facilities to carry out this research work.
 
Disclaimers
 
The views and conclusions expressed in this article are solely those of the authors and do not necessarily represent the views of their affiliated institutions. The authors are responsible for the accuracy and completeness of the information provided, but do not accept any liability for any direct or indirect losses resulting from the use of this content.
 
Informed consent
 
All animal procedures for experiments were in accordance with Committee of Experimental Animal care (273/PO/Re/S/2000/CCSEA, 24th November, 2000) and handling techniques were approved by the Institutional Animal Ethics Committee (IAEC), (CCSEA/IAEC/SBS/2025-01/04, 20th December, 2024).
The authors declare that there are no conflicts of interest regarding the publication of this article. No funding or sponsorship influenced the design of the study, data collection, analysis, decision to publish, or preparation of the manuscript.

  1. Abdul, H.M., Sarkhil, M.Z., Fayazuddin, M. and Ahmad, F. (2021). Peripheral analgesic activity of Moringa oleifera seeds- An experimental study. Asian Journal of Pharmacy and Pharmacology. 7(5): 200-203. 

  2. Abebe, W. (2002). Herbal medication: Potential for adverse interactions with analgesic drugs. Journal of Clinical Pharmacy and Therapeutics. 27(6): 391-401.

  3. Ahmad, F., Khan, R.A. and Rasheed, S. (1994). Preliminary screening of methanolic extracts of Celastrus paniculatus and Tecomella undulata for analgesic and anti-inflammatory activities. Journal of Ethnopharmacology. 42(3): 193- 198. https://doi.org/10.1016/0378-8741(94)90085.

  4. Anwar, F. and Bhanger, M.I. (2003). Analytical characterization of Moringa oleifera seed oil grown in temperate regions of Pakistan. Journal of Agricultural and Food Chemistry. 51(22): 6558-6563. https://doi.org/10.1021/jf0209894.

  5. Dwivedi, V. and Maurya, H. (2018). A comprehensive overview of Celastrus paniculatus seed oil intended for the management of human ailments. Indian Journal of Pharmaceutical and Biological Research. 6(2): 37-42.

  6. Dwivedi, V. and D’Souza, P. (2013). Antioxidant, analgesic and anti-inflammatory activities of the methanolic extract of Piper betle leaves. Avicenna Journal of Phytomedicine. 3(4): 325-334.

  7. Kanitta, J. and Wannee (2016). Moringa oleifera: A new challenge reducing heavy metal toxicity: A review. Indian Journal of Agricultural Research. 50(3): 199-205. doi: 10.18805/ijare.v0iOF.9361.

  8. Kulkarni, Y.A., Agarwal, S. and Garud, M.S. (2015). Effect of jyotishmati (Celastrus paniculatus) seeds in animal models of pain and inflammation. Journal of Ayurveda and Integrative Medicine. 6(2): 82-88. https://doi.org/10.4103/0975-9476.146540.

  9. Kumar, A., Panghal, S., Mallapur, S.S., Kumar, M., Ram, V. and Singh, B.K. (2009). Antiinflammatory activity of Piper longum fruit oil. Indian Journal of Pharmaceutical Sciences. 71(4): 454-456. https://doi.org/10.4103/0250-474X.57300. 

  10. Nagpal, K., Garg, M., Arora, D., Dubey, A. and Grewal, A.S. (2022). An extensive review on phytochemistry and pharmacological activities of Indian medicinal plant Celastrus paniculatus Willd. Phytotherapy Research. 36(5): 1930-1951. https://doi.org/10.1002/ptr.7424.

  11. Rathaur, A. (2024). Development of chhana spread by incorporating moringa (Moringa oleifera L.) leaves extract as a source of antioxidants and phenolics. Asian Journal of Dairy and Food Research. 43(1): 142-147. doi: 10.18805/ajdfr.DR-2082.

  12. Sarwa, K.K., Mazumder, B., Rudrapal, M. and Verma, V.K. (2015). Potential of capsaicin-loaded transfersomes in arthritic rats. Drug Delivery. 22(5): 638-646. https://doi.org/10.3109/10717544.2013.871601. 

  13. Sahu, L., Joshi, P.K., Rout, O.P. and Sahu, A. (2020). Phytochemical evaluation of Celastrus paniculatus seed oil extracted by a method used by ‘Uraanv’ tribe of Chhattisgarh. Journal of Ayurveda and Integrated Medical Sciences. 5(2): 57-65. https://doi.org/10.21760/jaims.5.2.9.

  14. Ugwuoke, C.U., Eze, G.E., Mgbenka, R.N., Omeje, B.A., Osinem, E.C. and Machebe, N.S. (2020). Effects of dietary intake of Moringa oleifera leaf meal on the growth performance of pullet chicks. Agricultural Science Digest. 40(2): 194- 198. doi: 10.18805/ag.D-189.
In this Article
Published In
Indian Journal of Animal Research

Editorial Board

View all (0)